Literature DB >> 20724467

Variability in the 3,4-methylenedioxymethamphetamine content of 'ecstasy' tablets in the UK.

David Michael Wood1, Vasoulla Stribley, Paul Ivor Dargan, Susannah Davies, David W Holt, John Ramsey.   

Abstract

BACKGROUND: Toxicity, such as hyperpyrexia, associated with the use of 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy') appears to be related to serum MDMA concentrations. However, there does not appear to be a similar association with the number of tablets ingested, suggesting variation in the tablet content of MDMA. Although work has shown this variation in other areas of the world, no studies have reported on the variation of MDMA content in UK ecstasy tablets.
METHODS: Ecstasy tablets seized from individuals attending nightclubs were analysed qualitatively to determine if they contained MDMA and quantitatively to determine the MDMA content per tablet.
RESULTS: The mean amount of MDMA hydrochloride in 101 seized ecstasy tablets was 58.7±22.9 mg per tablet, with a range of 20 mg to 131 mg per tablet. The majority (96.0%) of tablets contained less than 100 mg MDMA per tablet. There appeared to be a bimodal distribution of MDMA content at approximately 20-40 mg per tablet and 60-80 mg per tablet.
CONCLUSION: There is variability in the MDMA content of ecstasy tablets in the UK. This variability could potentially put users at increased risk of acute harm due to inadvertent excess ingestion of MDMA, as they are unaware of the differences in the MDMA content. Repeat sampling and quantification of MDMA content of ecstasy tablets in the UK will allow better education of users about the potential harms associated with the variability in the MDMA content. In addition, it will provide information to allow the monitoring of changes in not only the MDMA content, but also other adulterants, in ecstasy tablets.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20724467     DOI: 10.1136/emj.2010.092270

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  9 in total

Review 1.  Bath salts and synthetic cathinones: an emerging designer drug phenomenon.

Authors:  Christopher L German; Annette E Fleckenstein; Glen R Hanson
Journal:  Life Sci       Date:  2013-08-02       Impact factor: 5.037

2.  Deaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: a case series.

Authors:  Jennifer J E Nicol; Mark C Yarema; Graham R Jones; Walter Martz; Roy A Purssell; Judy C MacDonald; Ian Wishart; Monica Durigon; Despina Tzemis; Jane A Buxton
Journal:  CMAJ Open       Date:  2015-01-13

Review 3.  Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.

Authors:  Aryan Sarparast; Kelan Thomas; Benjamin Malcolm; Christopher S Stauffer
Journal:  Psychopharmacology (Berl)       Date:  2022-03-07       Impact factor: 4.415

4.  Detection of "bath salts" and other novel psychoactive substances in hair samples of ecstasy/MDMA/"Molly" users.

Authors:  Joseph J Palamar; Alberto Salomone; Marco Vincenti; Charles M Cleland
Journal:  Drug Alcohol Depend       Date:  2016-02-04       Impact factor: 4.492

5.  Willingness to provide a hair sample for drug testing among electronic dance music party attendees.

Authors:  Joseph J Palamar; Alberto Salomone; Charles M Cleland; Scott Sherman
Journal:  Subst Abus       Date:  2018-08-17       Impact factor: 3.716

6.  Behavioral effects and pharmacokinetics of (±)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) after intragastric administration to baboons.

Authors:  Amy K Goodwin; Melanie Mueller; Courtney D Shell; George A Ricaurte; Nancy A Ator
Journal:  J Pharmacol Exp Ther       Date:  2013-03-20       Impact factor: 4.030

7.  Comparison of the effects of abstinence on MDMA and cocaine self-administration in rats.

Authors:  Quenten Highgate; Susan Schenk
Journal:  Psychopharmacology (Berl)       Date:  2018-09-12       Impact factor: 4.530

8.  Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.

Authors:  Eduardo Ekman Schenberg
Journal:  Front Pharmacol       Date:  2018-07-05       Impact factor: 5.810

Review 9.  3,4-methylenedioxymethamphetamine (MDMA): current perspectives.

Authors:  Jerrold S Meyer
Journal:  Subst Abuse Rehabil       Date:  2013-11-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.